•
Dec 31, 2020
Allovir Q4 2020 Earnings Report
AlloVir reported full year 2020 financial results.
Key Takeaways
AlloVir reported its full-year 2020 financial results, highlighting the initiation of multiple clinical trials and FDA clearance for ALVR106. The company's cash, cash equivalents, and marketable securities totaled $356.3 million as of December 31, 2020.
Initiated Phase 3 pivotal clinical trial with Viralym-M for virus-associated hemorrhagic cystitis.
Initiated two additional Phase 2 proof-of-concept clinical trials with Viralym-M.
Initiated a proof-of-concept clinical trial with ALVR109 for COVID-19.
FDA cleared IND for ALVR106 for multi-respiratory viruses.